论文部分内容阅读
据近期出版的《癌症》杂志刊登的一篇综述报道,接受雄激素剥夺治疗(ADT)的前列腺癌患者的骨质丢失、骨质疏松和骨折的危险性增加。澳大利亚悉尼新南威尔士大学的主要研究人员Terence H.Diamond博士强调指出,事实上,对所有开始ADT治疗的男性的骨密度进行检测是非常必要的。妇女绝经后发生骨质疏松已是不争的事实。确定开始接受ADT治疗的前列腺癌高危患者并随后对其实施二磷酸盐类治疗是一种适宜的临床措施。横断面研究结果显示,接受ADT治疗的前列腺癌男性患者的骨密度与具有正常生殖腺功能的男子相比要低6.5％～17.3％。纵向研究发现,ADT治疗仅12个月所引致的腰椎骨丢失约为2％～8％;
A review published recently in the journal “Cancer” has reported an increased risk of bone loss, osteoporosis and fractures in prostate cancer patients receiving androgen deprivation therapy (ADT). Dr. Terence H. King, principal investigator at the University of New South Wales in Sydney, Australia, underlined the fact that it is necessary to test the bone density of all men who start ADT. It is an indisputable fact that postmenopausal women have osteoporosis. Identifying high-risk patients with prostate cancer who started ADT and subsequently administering diphosphates is an appropriate clinical strategy. Cross-sectional study showed that male patients with prostate cancer treated with ADT had a lower bone mineral density of 6.5% to 17.3% than men with normal gonadal function. Longitudinal study found that lumbar vertebral bone loss caused by only 12 months ADT treatment is about 2% to 8%;